INTRODUCTION
============

G protein--coupled receptors (GPCRs) form the largest and one of the most-studied families of cell-surface proteins. They respond to a vast array of cellular mediators, including hormones, neurotransmitters, lipids, nucleotides, peptides, ions, and photons. GPCRs have one of the widest therapeutic ranges and were estimated to be the targets of more than 30% of all marketed drugs ([@B24]; [@B50]). To be functional, these receptors must be correctly folded and transported to the proper location, usually the plasma membrane, in order to be activated by their respective ligands. Their seven-transmembrane structure with an extracellular N-terminus, alternating intra- and extracellular loops, and an intracellular C-terminus renders folding of GPCRs a complex process ([@B53]). Failure to achieve correct folding results in their retrotranslocation, ubiquitination, and endoplasmic reticulum (ER)-associated degradation ([@B12]). Dysregulation of GPCR folding, trafficking, and signaling contributes to a number of pathophysiological processes ([@B7]; [@B12]; [@B56]; [@B30]). Given the importance of these receptors, it is critical to understand the mechanisms that regulate their correct expression, folding, and export as nascent polypeptides, which, despite an increasing number of studies in this field of research, remain poorly characterized.

Secreted and membrane proteins possessing an N-terminal signal peptide are recognized by the signal recognition particle (SRP), leading to the cotranslational insertion of the polypeptides directly in the ER membrane through a translocon-dependent mechanism. Only 5--10% of known GPCRs contain a signal peptide that leads to their direct insertion into the ER membrane ([@B51]). Subsequent folding, posttranslational modifications, and trafficking are controlled by ER-resident proteins and chaperones ([@B46]). However, little is known regarding what happens to the majority of GPCRs that do not contain signal sequences in their N-termini. Studies have shown that transmembrane segments of GPCRs can act as signal anchor (SA) sequences and be recognized by the SRP, but it remains unclear how and when such recognition occurs ([@B3]; [@B51]). Unlike the signal peptide, the SA is not cleaved after translocon-mediated insertion into the ER. Since translation of membrane proteins lacking a signal peptide begins in the cytosol, the SRP has a very short window of time to bind the translating ribosome and recognize the SA, because their interaction is inversely proportional to the polypeptide length ([@B9]). If the SRP is unable to bind the SA, the synthesized protein is exposed to the cytosolic environment, which can result in aggregation and misfolding ([@B58]). To prevent this from happening, eukaryotic cells possess chaperone proteins that assist the folding process of nascent polypeptides, maintaining them in an intermediate state of folding competence for posttranslational translocation in subcellular compartments. Two complexes of chaperone proteins have been identified to interact posttranslationally with near nascent proteins and seem to affect their translocation into the ER. The first is the well-known 70-kDa heat shock protein (Hsp70) system, and the second is the tailless complex polypeptide 1 (TCP-1), a group II chaperonin, also known as the CCT/TCP-1 ring complex (TRiC complex; [@B15]; [@B41]). The exact sequence of posttranslational events leading to ER insertion is not fully understood, but studies have proposed a three-step process. First, the nascent peptide emerging from ribosomes is able to interact with the nascent polypeptide-associated complex or the SRP, which both regulate translational flux ([@B28]). However, once translation is completed, these proteins are no longer able to bind the polypeptide. Second, Hsp70 and/or CCT/TRiC complexes bind polypeptides to maintain a translocable state by preventing premature folding, misfolding, and aggregation ([@B35]; [@B13]). Third, ER-membrane insertion is mediated by the translocon, which strips away the cytosolic chaperones. This process is called the posttranslational translocation pathway ([@B36]).

CCT/TRiC is a large cytosolic chaperonin complex of ∼900 kDa composed of two hetero-oligomeric stacked rings able to interact with nascent polypeptides, which mediates protein folding in an ATP-dependent manner and prevents aggregation in eukaryotes ([@B29]). Each ring consists of eight different subunits (CCT1 to CCT8) that share ∼30% sequence homology, particularly in their equatorial domains, which mediate interactions between subunits ([@B55]). CCT/TRiC was originally characterized for its role in the folding of α-actin ([@B32]). In recent years, the list of identified substrates for this complex has grown in both number and variety. For example, it has been shown that CCT/TRiC can bind and/or help the folding of different WD-repeat proteins like the G-protein β subunits ([@B42]), STAT3 ([@B27]), the von Hippel-Lindau (VHL) protein ([@B35]), and even membrane proteins such as the peroxisome membrane protein Pmp22p ([@B40]) and the cell-surface receptor LOX-1 ([@B5]). The central cavity formed by the two stacked rings protects the newly synthesized polypeptide against aggregation in the crowded environment of the cytosol. This large cavity can accommodate a wide range of protein sizes from 20 to 200 kDa ([@B14]). It was shown that CCT/TRiC can cotranslationally bind nascent polypeptides exposing at least 50 amino acids outside of the ribosome exit channel, but this number can vary between the different substrates ([@B33]).

Here we report a direct and functional interaction between GPCRs and the chaperonin containing TCP-1 subunit eta (CCT7). We provide evidence that CCT7 is involved in preventing aggregation of GPCRs and in regulating their expression, maturation, and transport to the cell surface. To our knowledge, this is the first demonstration of a functional interaction between GPCRs and the CCT/TRiC complex.

RESULTS
=======

CCT7 interacts with the β-isoform of thromboxane A~2~ receptor (TPβ) and β~2~-adrenergic receptor (β~2~AR)
----------------------------------------------------------------------------------------------------------

A yeast two-hybrid screen was performed using the C-terminus of TPβ as bait with a human HeLa cell MATCHMAKER cDNA library. Roughly 3 × 10^6^ clones were screened, resulting in more than 600 positives. Approximately 200 of these clones showed strong growth on selective yeast medium (Trp^−^, Leu^−^, His^−^, and Ade^−^) and were isolated, characterized by dideoxy sequencing, and then aligned using the NCBI BLAST alignment search tool. Five independent clones covering the full-length CCT7 coding sequence were identified in this screen. As shown in [Figure 1A](#F1){ref-type="fig"}, only yeast transformed with the pAS2.1-TPβ C-terminus and pGAD-CCT7 showed strong growth on selective Trp^−^, Leu^−^, His^−^, and Ade^−^ yeast medium, indicating that CCT7 interacts with the TPβ C-terminus.

![TPβ and β~2~AR interact with CCT7. (A) A yeast two-hybrid screen was performed using the TPβ C-terminus portion as bait on a human HeLa cell MATCHMAKER cDNA library. The interaction between CCT7 and the TPβ C-terminus was confirmed by the use of the selective yeast medium Trp^−^, Leu^−^, His^−^, and Ade^−^. (B) Lysates of HEK 293 cells transiently expressing HA-TPβ and CCT7-MYC alone or together were immunoprecipitated with HA-specific monoclonal antibody, and immunoblotting was performed with HA-specific HRP and MYC-specific HRP-conjugated antibodies. (C) Lysates of HEK 293 cells transiently expressing FLAG-β~2~AR and CCT7-MYC alone or together were immunoprecipitated with FLAG-specific monoclonal antibody, and immunoblotting was performed with Flag-specific polyclonal and MYC-specific HRP-conjugated antibodies. (D) HEK 293 cells lysates were incubated with either nonspecific goat or CCT7-specific goat polyclonal antibodies, and immunoblotting was performed using the same CCT7-specific and a β~2~AR-specific rabbit polyclonal antibody. All blots shown are representative of at least three independent experiments. IB, immunoblotting; IP, immunoprecipitation.](3800fig1){#F1}

Interestingly, we also identified CCT7 as a putative interactor of the β~2~AR using a gel-free proteomic approach, but the interaction and its functional consequences were not characterized ([@B47]). To assess the interaction between CCT7 and both GPCRs in a cellular context, we performed immunoprecipitation experiments in HEK 293 cells transfected with pcDNA3-FLAG-β~2~AR or pcDNA3-HA-TPβ and pcDNA3-CCT7--c-myc epitope (MYC). Cell lysates were incubated with FLAG-specific or hemagglutinin (HA)-specific monoclonal antibodies, and coimmunoprecipitation of CCT7 was detected by Western blot analysis using a Myc-specific antibody. CCT7 coimmunoprecipitated with both receptors ([Figure 1, B and C](#F1){ref-type="fig"}), confirming that CCT7 forms a complex with either TPβ or β~2~AR in cells. Importantly, our data further show that the interaction can be detected endogenously. Indeed, HEK 293 cell lysates were incubated with CCT7-specific or nonspecific goat antibodies and coimmunoprecipitation of endogenous β~2~AR was detected by Western blot analysis using a β~2~AR-specific antibody. Endogenous β~2~AR was coimmunoprecipitated only when endogenous CCT7 was immunoprecipitated ([Figure 1D](#F1){ref-type="fig"}).

Depletion of CCT7 impairs β~2~AR and TPβ total and cell-surface expression
--------------------------------------------------------------------------

To characterize the functional role of CCT7 interactions with β~2~AR and TPβ, we first investigated the effect of CCT7 depletion on total expression of the receptors by Western blot. HEK 293 cells stably expressing HA**-**β~2~AR or HA-TPβ were transfected with control or CCT7 dicer-substrate short interfering RNAs (DsiRNAs). [Figure 2, A and B](#F2){ref-type="fig"}, shows that the partial depletion of CCT7 leads to decreased total protein expression of both receptors. Densitometry analyses of multiple independent experiments revealed that CCT7 depletion resulted in a loss of 42 and 37% in total receptor expression for TPβ and β~2~AR, respectively ([Figure 2, C and D](#F2){ref-type="fig"}). We then assessed the importance of CCT7 expression on the cell-surface expression of β~2~AR, TPβ, and thromboxane A~2~ receptor α-isoform (TPα), a shorter isoform of TP compared to TPβ generated by alternative splicing of the receptor C-terminus ([@B44]). HEK 293 cells expressing HA-tagged TPβ, TPα, or β~2~AR were transfected with control or CCT7 DsiRNAs and receptor cell-surface expression was measured by enzyme-linked immunosorbent assay (ELISA). CCT7 depletion significantly decreased TPβ cell-surface expression by 50% ([Figure 2E](#F2){ref-type="fig"}), whereas cell-surface expression of TPα and β~2~AR was less affected, with reductions of 30 and 22%, respectively ([Figure 2, F and G](#F2){ref-type="fig"}).

![CCT7 depletion impairs TPβ and β~2~AR total and cell-surface expression. HEK 293 cells stably expressing HA-TPβ (A) or HA-β~2~AR (B) were transfected with control DsiRNA (DsiCtrl) or CCT7 DsiRNA (DsiCCT7), and lysates were immunoblotted with HA-specific HRP-conjugated, CCT7-specific and GAPDH-specific antibodies. Densitometry was performed on the Western blots to quantify relative expression of HA-TPβ (C) and HA-β~2~AR (D) in cells treated with CCT7 DsiRNA compared with control DsiRNA-transfected cells (100%) and normalized to GAPDH expression. Densitometry was performed using ImageJ software, and the results are presented as mean ± SD of at least four independent experiments. Cell-surface receptor expression was measured in HEK 293 cells expressing HA-TPβ (E), HA-TPα (F), or HA-β~2~AR (G) transfected with control or CCT7 DsiRNAs by ELISA using a monoclonal HA-specific antibody as described in *Materials and Methods*. Results are shown as a percentage of cell-surface receptor expression when cells were transfected with CCT7 DsiRNA compared with control DsiRNA condition (100%). (H) Lysates of HEK 293 cells transiently expressing FLAG-TPβ or FLAG-β~2~AR and HA-Hsp90 alone or together were immunoprecipitated with FLAG-specific monoclonal antibody, and immunoblotting was performed with FLAG-specific polyclonal and HA-specific HRP-conjugated antibodies. Densitometry on Western blots of five independent experiments are reported in the graphic and expressed as a ratio of HSP90 co-IP on receptors IP. Results are presented as mean ± SEM of at least four independent experiments. IB, immunoblotting; IP, immunoprecipitation.](3800fig2){#F2}

In mammals, nascent polypeptides emerging from ribosomes are bound by Hsc70, which operates in concert with the CCT/TRiC complex in the folding of polypeptides. Alternatively, polypeptides can be passed to Hsp90 ([@B61]). In an attempt to address why CCT7 depletion affected the cell-surface expression of TPβ more significantly than that of β~2~AR, we compared the ability of both receptors to interact with Hsp90. Lysates of HEK 293 cells expressing FLAG-β~2~AR or FLAG-TPβ and HA-Hsp90 were immunoprecipitated with a Flag-specific antibody, and Hsp90 interaction was studied by Western blot analysis with an HA-specific monoclonal antibody ([Figure 2H](#F2){ref-type="fig"}). Interestingly, significantly more Hsp90 protein coimmunoprecipitated with β~2~AR than with TPβ.

CCT7 colocalizes with β~2~AR and TPβ and regulates their intracellular distribution
-----------------------------------------------------------------------------------

Confocal microscopy was performed in HEK 293 cells stably expressing HA-β~2~AR or HA-TPβ that were transfected or not with control or CCT7 DsiRNAs and labeled with HA- and CCT7-specific antibodies. [Figure 3, Ab and Bb](#F3){ref-type="fig"}, shows the levels of nonspecific secondary antibody--associated staining compared with the labeling obtained with the CCT7-specific antibody ([Figure 3, Af and Bf](#F3){ref-type="fig"}). Endogenous CCT7 displayed cytosolic and nuclear localization in control DsiRNA-treated cells. HA-TPβ was distributed at the plasma membrane and in intracellular compartments in nontreated and control DsiRNA-transfected cells ([Figure 3A, c and g](#F3){ref-type="fig"}), as we reported before ([@B54]; [@B37]). Under the same conditions, HA-β~2~AR was primarily localized to the plasma membrane with some intracellular labeling ([Figure 3B, c and g](#F3){ref-type="fig"}). Analysis of merged images revealed that CCT7 mainly colocalized with both receptors in the juxtanuclear region of the cell ([Figure 3, Ah and Bh](#F3){ref-type="fig"}). Transfection of CCT7 DsiRNAs significantly diminished expression of endogenous CCT7 ([Figure 3, Aj and Bj](#F3){ref-type="fig"}) and caused a marked redistribution of both receptors to an intracellular and juxtanuclear localization, which was more pronounced for HA-TPβ ([Figure 3, Ak and Bk](#F3){ref-type="fig"}), in agreement with data obtained in receptor cell-surface expression experiments ([Figure 2, E and G](#F2){ref-type="fig"}). Depletion of CCT7 also appeared to decrease receptor-associated fluorescence for both receptors, also supporting our findings from Western blot analyses ([Figure 2, A and B](#F2){ref-type="fig"}).

![CCT7 colocalizes with TPβ and β~2~AR and regulates their intracellular distribution. Confocal microscopy was performed on HEK 293 cells stably expressing HA-TPβ (A) or HA-β~2~AR (B) treated with control or CCT7 DsiRNAs. Cells were fixed, permeabilized, and labeled with goat nonspecific IgG as a control, goat anti-CCT7 IgG, and mouse anti-HA IgG. Secondary antibodies used were Alexa Fluor 488--conjugated anti-mouse IgG and Texas red--conjugated anti-goat IgG. Cells were then stained with 4′,6-diamidino-2-phenylindole (DAPI) to visualize nuclei (a, e, and i). The fourth panel on the right represents a merged image of the blue, green, and red signals where the areas with high degree of colocalization between green-labeled receptors (c, g, and k) and red-labeled CCT7 (f and j) appear yellow (h). Approximately 88% of the 250 CCT7-depleted cells observed showed juxtanuclear accumulation of TPβ compared with 7% of the 250 control cells. Images shown are single confocal slices representative of at least four independent experiments and more than 250 observed cells. Scale bars: 10 μm.](3800fig3){#F3}

CCT7 depletion induces accumulation of misfolded receptors in intracellular aggregates
--------------------------------------------------------------------------------------

Because the distribution of the receptors was reminiscent of Golgi localization in cells transfected with CCT7 DsiRNAs, we performed colocalization studies between TPβ and GM130, a Golgi marker, in CCT7-depleted HEK 293 cells ([Figure 4A](#F4){ref-type="fig"}). Partial colocalization was observed between the receptor and GM130 ([Figure 4Ad](#F4){ref-type="fig"}). The relocalization of misfolded proteins to a juxtanuclear localization and a spatial overlap with the Golgi apparatus have been demonstrated to be associated with the formation of aggresomes ([@B25]; [@B22]; [@B48]). Aggresomes are made up of aggregated inclusion bodies and misfolded proteins ([@B57]). Given the function of CCT7 in protein folding, we reasoned that the receptors could be found in aggresomes in CCT7-depleted cells. Confocal microscopy was performed as above in HEK 293 cells stably expressing HA-TPβ or HA-β~2~AR transfected with control or CCT7 DsiRNAs ([Figure 4, B and D](#F4){ref-type="fig"}). Cells were also stained with a probe, the PROTEOSTAT dye, designed to detect aggresomes by recognition of inclusion bodies and misfolded proteins. Low levels of colocalization were detected between the receptors and aggresomes under control conditions represented by low Mander's colocalization coefficients of 0.03 and 0.01 for TPβ and β~2~AR, respectively ([Figure 4, C and E](#F4){ref-type="fig"}). However, CCT7 depletion resulted in increased colocalization of both receptors with aggresomes in a juxtanuclear region ([Figure 4, Bf and Df](#F4){ref-type="fig"}). This was more drastic for TPβ than for β~2~AR, as indicated by Mander's colocalization coefficients in CCT7-depleted cells of 0.84 and 0.30 for TPβ and β~2~AR, respectively ([Figure 4, C and E](#F4){ref-type="fig"}). These results indicate that CCT7 depletion induced an accumulation of misfolded TPβ and β~2~AR in intracellular aggregates, notably more pronounced for the former. It is also interesting to observe an overall augmentation of the aggresome staining across the cytosol of CCT7-depleted cells compared with the control ([Figure 4, Be and De](#F4){ref-type="fig"}). This is probably caused by the detection, by the PROTEOSTAT dye, of other broadly distributed misfolded proteins.

![CCT7 depletion causes redistribution of receptors in aggresomes. (A) HEK 293 cells stably expressing HA-TPβ transfected with CCT7 DsiRNA were fixed, permeabilized, and labeled with a rabbit anti-HA IgG and a mouse anti-GM130. Alexa Fluor 488--conjugated anti-rabbit IgG and Alexa Fluor 633--conjugated anti-mouse IgG were used as secondary antibodies. The fourth panel (d) represents a merge image of the blue (a), green (b), and red (c) signals. High degree of colocalization between the red and green signals appears in yellow. HEK 293 cells stably expressing HA-TPβ (B) or HA-β~2~AR (D) were treated with control or CCT7 DsiRNAs. The cells were fixed, permeabilized, and labeled with mouse anti-HA IgG and stained with PROTEOSTAT aggresome dye. We used Alexa Fluor 633--conjugated anti-mouse IgG as secondary antibody. The third image on the right represents a merged image (c and f) of the green and red signals where the areas with high degree of colocalization between the green signal of the receptors (a and d) and red signal of the aggresome (b and e) appear yellow. Scale bars: 10 μm. Images shown are single confocal slices representative of at least four independent experiments and more than 250 observed cells. (C, E) Mander's colocalization coefficients represent the ratio of the green signal of the receptors overlapping the red signal of the aggresome and were calculated from at least 100 cells per condition. Results are presented as mean ± SEM.](3800fig4){#F4}

Determination of the CCT7-binding domain on β~2~AR and TPβ
----------------------------------------------------------

To establish whether or not the interaction of CCT7 with receptors could be direct, and if so to determine its binding domains on β~2~AR and TPβ, we performed in vitro binding assays with purified forms of recombinant intracellular loops (ICL) or C-termini (CT) of both receptors fused to glutathione *S*-transferase (GST) along with purified CCT7-MYC fused with a hexa-His tag (His~6~-CCT7-MYC). We also investigated whether CCT7 interacted with the C-terminus of TPα, a C-terminal spliced isoform of TP that shares its first 328 amino acids with TPβ. Results presented in [Figure 5, A and B](#F5){ref-type="fig"}, show a binding reaction between His~6~-CCT7-MYC bound to nickel--nitrilotriacetic acid--agarose beads and GST-TPβ-CT, GST-β~2~AR-CT, and GST-ICL3 of both receptors. No significant interaction was observed with other intracellular loops or with GST-TPα-CT ([Figure 5A](#F5){ref-type="fig"}). These results indicate that CCT7 can interact directly with the C-terminus and the third intracellular loop of β~2~AR and TPβ. However, no interaction was detected between CCT7 and the TPα C-terminus. It thus appeared that the CCT7 interaction with the TPβ C-terminus occurs on sequences that differ between the TPβ and TPα C-termini ([Figure 6A](#F6){ref-type="fig"}). To elucidate the region of the TPβ C-terminus involved in interacting with CCT7, we used progressive HA-tagged C-terminal deletion mutant constructs of the receptor to perform CCT7 coimmunoprecipitation experiments in HEK 293 cells. As shown in [Figure 6B](#F6){ref-type="fig"}, the majority of the CCT7 coimmunoprecipitation was lost with the HA-TPβ 328-Stop mutant compared with the wild-type receptor but recovered nearly to wild-type receptor levels with the HA-TPβ 337-Stop mutant, as supported by densitometry analysis of four independent experiments. These data suggest that determinants found between residues 328 and 337 in the TPβ C-terminus are essential for the interaction with CCT7 in a cellular context. Amino acids in the ICL3 may participate in the CCT7 interaction but are not sufficient, as both TPα and the TPβ 328-Stop mutant failed to coimmunoprecipitate CCT7.

![Identification of the CCT7-binding domains on TPβ and β~2~AR. (A) His pull-down assays were carried out using purified hexahistidine (His)~6~-CCT7-MYC bound to nickel--nitrilotriacetic acid--agarose beads incubated with purified GST or GST fused to the TP C-termini (GST-TPβ-CT and GST-TPα-CT) and intracellular loops (GST-TPβ-ICL). (B) His pull-down assays were carried out using purified (His)~6~-CCT7-MYC bound to nickel--nitrilotriacetic acid--agarose beads incubated with purified GST or GST fused to the β~2~AR C-terminus (GST-β~2~AR-CT) and intracellular loops (GST-β~2~AR-ICL). The binding of GST-fusion proteins in A and B was detected by immunoblotting with a GST-specific HRP-conjugated antibody, and the (His)~6~-CCT7-MYC present in the binding reactions was detected with a MYC-specific HRP-conjugated antibody. Blots shown are representative of at least five independent experiments.](3800fig5){#F5}

![TPβ Trp^334^ is a major determinant for CCT7 interaction. (A) Schematic representation of TPβ and TPα C-termini. The TPβ region important for CCT7 interaction is underlined in blue. The green, linked amino acids represent residues showing similarity or identity between TPβ and TPα. Shown in red are TPβ Trp^334^ and TPα Gln^333^. (B) Lysates of HEK 293 cells transiently expressing the indicated HA-TPβ constructs alone or with CCT7-MYC were immunoprecipitated with a HA-specific monoclonal antibody and analyzed by immunoblotting with MYC- and HA-specific HRP-conjugated antibodies. HA-TPβ 328, 337, 344, and 351 indicate that a stop codon was introduced after the corresponding amino acids. Densitometry on Western blots of four independent experiments are reported in the graphic and expressed as a relative ratio of CCT7 co-IP on receptors IP. (C) Lysates of HEK 293 cells transiently expressing HA-TPβ, HA-TPβ W334Q, HA-TPα, or HA-TPα Q333W alone or with CCT7-MYC were immunoprecipitated with a HA-specific monoclonal antibody and analyzed by immunoblotting with MYC- and HA-specific HRP-conjugated antibodies. Densitometry on Western blots of five independent experiments are reported in the graphic and expressed as a relative ratio of CCT7 co-IP on receptors' IP. IB, immunoblotting; IP, immunoprecipitation.](3800fig6){#F6}

Trp^334^ of TPβ is involved in the interaction with CCT7
--------------------------------------------------------

We compared the amino acid sequences between residues 328 and 337 of TPα and TPβ ([Figure 6A](#F6){ref-type="fig"}), based on the above results. Because the CCT complex can interact with bulky hydrophobic amino acids in its client proteins ([@B52]), the Trp^334^ residue of TPβ and Gln^333^ of TPα particularly stood out as interesting differences between the two receptor forms. We thus decided to exchange the residues between the two receptors to generate the TPβ W334Q and TPα Q333W mutants and studied whether this altered the CCT7-binding properties of the receptors. CCT7 coimmunoprecipitation experiments with these HA-tagged receptor mutants in HEK 293 cells revealed that the TPβ W334Q mutation severely impaired the interaction with CCT7 by ∼85% compared with wild-type TPβ ([Figure 6C](#F6){ref-type="fig"}, lane 6 vs. lane 4, and densitometry, right panel). Interestingly, the reverse mutation in TPα (TPα Q333W) strongly promoted the interaction with CCT7 compared with wild-type TPα to levels comparable to wild-type TPβ ([Figure 6C](#F6){ref-type="fig"}, lane 10 vs. lane 8, and densitometry, right panel). Taken together, these data show that Trp^334^ of TPβ is a critical determinant in the interaction with CCT7.

Role of Trp^334^ in TPβ maturation
----------------------------------

Closer observation by Western blot analysis of the migration patterns of the TPβ W334Q and TPα Q333W mutants from cell lysates revealed that they were different from their respective wild-type counterparts. [Figure 7A](#F7){ref-type="fig"} shows that wild-type HA-TPβ was detected as a major form at ∼40 kDa and a minor form at ∼70 kDa. In contrast, HA-TPβ W334Q displayed the opposite pattern, with minor and major forms at ∼40 and ∼70 kDa, respectively. The latter was reminiscent of the expression pattern shown by wild-type HA-TPα ([Figure 7B](#F7){ref-type="fig"}), which migrated as a prominent form in the ∼50--55 kDa range and as a minor form at ∼35 kDa. On the other hand, the TPα Q333W mutation induced a redistribution of the higher molecular form of the receptor toward the lower ∼35 kDa form, analogous to the distribution of the wild-type HA-TPβ.

![Trp^334^ is involved in TPβ maturation and cell-surface expression. (A) Lysates of HEK 293 cells transiently expressing HA-TPβ or HA-TPβ W334Q were analyzed by immunoblotting with HA-specific HRP-conjugated and GAPDH antibodies. (B) Lysates of HEK 293 cells transiently expressing HA-TPα or HA-TPα Q333W were analyzed by immunoblotting with HA-specific HRP-conjugated and GAPDH-specific antibodies. (C) Lysates from HEK 293 cells transiently expressing HA-TPβ or HA-TPα were subject to deglycosylation with Endo Hf as described in *Materials and Methods*. Immunoblotting was performed using HA-specific HRP-conjugated and GAPDH-specific antibodies. The blots shown are representative of three separate experiments. IB, immunoblotting. (D) Cell-surface receptor expression was measured in HEK 293 cells transiently expressing HA-TPβ, HA-TPβ W334Q, HA-TPα, or HA-TPα Q333W by ELISA using a monoclonal HA-specific antibody as described in *Materials and Methods*. The results are shown as the percentage of cell-surface receptor expression compared with HA-TPβ (TPβ, 100%). Results represent mean ± SEM of at least four independent experiments.](3800fig7){#F7}

We previously reported that the TPβ ∼70 kDa and TPα ∼50-55 kDa forms corresponded to glycosylated dimers of the receptors measured using treatment with peptide N-glycosidase F, which removes all types of N-linked oligosaccharides from glycoproteins ([@B31]). Here we further analyzed the glycosylation patterns of TP isoforms with endoglycosidase H (Endo Hf), an N-glycosidase that selectively removes unprocessed high mannose--type N-linked oligosaccharides present on ER-resident glycoproteins. Glycosylated TP receptor proteins that have undergone trimming in the Golgi will be resistant to Endo Hf treatment. Lysates of HEK 293 cells expressing HA-TPβ or HA-TPα were treated with Endo Hf and then analyzed by Western blot. As shown in [Figure 7C](#F7){ref-type="fig"}, the larger HA-TPβ ∼70 kDa and TPα ∼50-55 kDa forms were predominantly unaltered, whereas the lower forms of the receptors were reduced in size upon Endo Hf treatment. Altogether our present data, along with our earlier results ([@B31]), indicate that the lower molecular weight bands of TPβ and TPα are immature monomeric forms of the receptors present in the ER. On the other hand, the higher molecular weight Endo Hf--resistant forms represent dimeric TP receptors that have undergone complex glycosylation in the Golgi. Consistent with this, our results suggest that the HA-TPβ W334Q mutation promoted receptor maturation through the Golgi toward a glycosylated receptor dimer ([Figure 7A](#F7){ref-type="fig"}). In contrast, the TPα Q333W receptor displayed impaired maturation compared with wild-type TPα ([Figure 7B](#F7){ref-type="fig"}).

Using ELISAs in HEK 293 cells, we then evaluated whether the effects of the TPβ W334Q and TPα Q333W substitutions on receptor maturation were reflected in receptor cell-surface expression. Compared with wild-type HA-TPβ, cell-surface expression of HA-TPβ W334Q was increased by more than 200% to reach similar levels as HA-TPα ([Figure 7D](#F7){ref-type="fig"}). Conversely, HA-TPα Q333W detection at the cell membrane was reduced by 50% compared with wild-type HA-TPα (115 vs. 239%), akin to wild-type HA-TPβ expression levels. The effect of the TPβ W334Q mutation on cell-surface expression of the receptor was also studied by confocal microscopy. HEK 293 cells transiently expressing HA-TPβ or HA-TPβ W334Q were labeled with an HA-specific antibody to visualize the receptors and with a CCT7-specific antibody to detect endogenous CCT7 ([Figure 8A](#F8){ref-type="fig"}). As we reported before, wild-type TPβ exhibited plasma membrane staining accompanied by strong intracellular localization ([Figure 8Ac](#F8){ref-type="fig"}). On the other hand, the TPβ W334Q mutant displayed robust membrane localization ([Figure 7Ag](#F7){ref-type="fig"}). Quantification of receptor immunofluorescence was carried out on 100 cells for each receptor construct. [Figure 8B](#F8){ref-type="fig"} shows that 25% of wild-type TPβ immunofluorescence was found at the plasma membrane, compared with 55% for the TPβ W334Q mutant, a roughly twofold difference, confirming our cell-surface expression data obtained by ELISA ([Figure 7D](#F7){ref-type="fig"}). We also observed that TPβ colocalized more significantly with CCT7 than did the TPβ W334Q mutant ([Figure 8A, d and h](#F8){ref-type="fig"}). Quantification of CCT7 colocalization with the two receptor constructs revealed Mander's colocalization coefficients of 0.43 for TPβ and 0.12 for TPβ W334Q ([Figure 8C](#F8){ref-type="fig"}). This marked decrease in CCT7 colocalization with the TPβ W334Q mutant is in line with the virtual lack of detectable coimmunoprecipitation between the two proteins ([Figure 6C](#F6){ref-type="fig"}).

![Characterization of the TPβ Trp^334^ mutant. (A) Confocal microscopy was performed on HEK 293 cells transiently expressing HA-TPβ (a--d) or TPβ W334Q (e--h). Cells were fixed, permeabilized, and labeled with goat anti-CCT7 IgG and mouse anti-HA IgG antibodies. Secondary antibodies used were Alexa Fluor 488--conjugated anti-mouse IgG and Texas red--conjugated anti-goat IgG. Cells were then stained with DAPI to visualize nuclei (a and e). The fourth panel on the right represents a merged image of the blue, green and red signals where the areas with high degree of colocalization between green-labeled receptors (c and g) and red-labeled CCT7 (b and f) appear yellow (d and h). Images shown are single confocal slices representative of at least four independent experiments and more than 100 observed cells. Scale bars: 10 µm. (B) Quantification of the membrane on total receptor fluorescence ratio was calculated using ImageJ software and was performed on at least 100 cells per condition. (C) Mander's colocalization coefficients represent the ratio of the green signal of the receptors overlapping the red signal of the aggresome and were calculated from at least 100 cells per condition. Results are presented as mean ± SEM.](3800fig8){#F8}

Next we assessed the effect of CCT7 depletion on the colocalization of the TPβ W334Q mutant with the aggresome. Confocal microscopy experiments showed that the receptor mutant, in the presence of CCT7 DsiRNAs, was readily detected at the cell surface ([Figure 9Ad](#F9){ref-type="fig"}) but also redistributed to the aggresome ([Figure 9Af](#F9){ref-type="fig"}). Quantification of the colocalization between the TPβ W334Q mutant and the aggresome yielded a Mander's coefficient of colocalization of 0.51 when CCT7 was depleted compared with 0.10 when the cells were transfected with control DsiRNAs ([Figure 9B](#F9){ref-type="fig"}). These results indicate that the receptor mutant is still affected by CCT7 depletion in terms of redistribution to the aggresome but in a less drastic way than was wild-type TPβ ([Figure 4, B and C](#F4){ref-type="fig"}, Mander's coefficient of 0.84). Taken together, our results indicate that Trp^334^ of TPβ interacts with CCT7 and plays an important role in the maturation and cell-surface expression of the receptor.

![Targeting of the TPβ Trp^334^ mutant to the aggresome is diminished compared with wild-type TPβ in CCT7-depleted cells. (A) HEK 293 cells transiently expressing HA-TPβ W334Q were treated with control or CCT7 DsiRNAs. The cells were fixed, permeabilized, labeled with mouse anti-HA IgG, and stained with PROTEOSTAT aggresome dye. Alexa Fluor 633--conjugated anti-mouse IgG was used as the secondary antibody. The third images represent a merged image (c and f) of the green and red signals where the areas with high degree of colocalization between the green signal of the receptors (a and d) and red signal of the aggresome (b and e) appear yellow. Scale bars: 10 μm. Images shown are single confocal slices representative of at least four independent experiments and more than 250 observed cells. (B) Mander's colocalization coefficients represent the ratio of the green signal of the receptor overlapping the red signal of aggresomes and were calculated from at least 100 cells per condition. Results are presented as mean ± SEM.](3800fig9){#F9}

CCT7 interacts with other GPCRs
-------------------------------

Finally, knowing that CCT7 can interact with the β~2~AR and TPβ but not with TPα, we wanted to extend our coimmunoprecipitation studies to a few other GPCRs. Lysates of HEK 293 cells transiently expressing HA-tagged rat μ-opioid receptor (MOR; [Figure 10A](#F10){ref-type="fig"}), FLAG-tagged rat δ-opioid receptor (DOR; [Figure 10B](#F10){ref-type="fig"}), or FLAG-tagged prostaglandin D~2~ receptor (DP; [Figure 10C](#F10){ref-type="fig"}) with or without CCT7-MYC were incubated with HA- or FLAG-specific antibodies. Coimmunoprecipitation of CCT7 was detected by Western blot analysis using a Myc-specific antibody. Coimmunoprecipitation of CCT7 was observed with each of the three receptors. Our data suggest that CCT7 can interact with various GPCRs, but not all, and that it can display specificity at the interaction and functional levels between different receptors.

![CCT7 coimmunoprecipitates with other GPCRs. (A) Lysates of HEK 293 cells transiently expressing HA-MOR (HA-tagged rat μ-opioid receptor) alone or with CCT7-MYC were immunoprecipitated with an HA-specific monoclonal antibody and analyzed by immunoblotting with MYC- and HA-specific HRP-conjugated antibodies. Lysates of HEK 293 cells transiently expressing FLAG-DOR (FLAG-tagged rat δ-opioid receptor; B) or FLAG-DP (FLAG-tagged prostaglandin D~2~ receptor; C) alone or with CCT7-MYC were immunoprecipitated with a FLAG-specific monoclonal antibody and analyzed by immunoblotting with FLAG-specific polyclonal and HA-specific HRP-conjugated antibodies. The blots shown are representative of three separate experiments. IB, immunoblotting; IP, immunoprecipitation.](3800fig10){#F10}

DISCUSSION
==========

GPCRs contain seven highly hydrophobic α-helical membrane-spanning domains and are particularly prone to misfolding and aggregation ([@B1]). While an increasing number of studies have described the chaperones and other associated proteins involved in GPCR folding and maturation from the ER to the plasma membrane ([@B53]), our knowledge of the chaperone proteins that interact with nascent GPCR polypeptides remains limited. In the present study, we have characterized functional interactions between two GPCRs and CCT7, a subunit of the CCT/TRiC complex that binds to nascent polypeptides ([@B33]).

CCT/TRiC is distinguished from other chaperones by its unique ring-shaped structure, which forms a central cavity that serves as a folding chamber for substrates ([@B60]). Bioinformatics analysis of the CCT/TRiC substrates noted that the CCT/TRiC interactome is enriched in large, hydrophobic proteins with intricate topologies predicted to be slow folding and aggregation prone and belonging to oligomeric protein complexes. On the other hand, CCT/TRiC could fold monomeric subunits and maintain them in an assembly-competent state until association with oligomeric partners ([@B60]). Here we provide evidence that the CCT/TRiC chaperonins prevent aggregation and participate in the folding and maturation of the complex seven-transmembrane GPCR proteins known to form oligomeric structures between receptor units and with signaling partners during their biogenesis ([@B17]; [@B18]).

We first identified the interaction between CCT7 and TPβ by yeast two-hybrid screening with the C-terminus of the receptor. We also detected all of the eight CCT subunits as potential β~2~AR-binding partners in liquid chromatography--tandem mass spectrometry proteomics studies ([@B47]). Our data showed that TPβ and β~2~AR can interact directly with CCT7 through their third intracellular loops and their C-termini. The interaction was confirmed by coimmunoprecipitation experiments in a cellular context in overexpression settings for both receptors but notably also between endogenous CCT7 and β~2~AR proteins. Further analysis also showed that CCT7 coimmunoprecipitated in HEK 293 cells with other GPCRs, such as the prostaglandin D~2~ DP1, and the μ- and δ-opioid receptors, suggesting that CCT7 may be involved in a general mechanism of GPCR biogenesis.

TPβ displays prominent intracellular localization in our system, which is consistent with the fact that it is prone to ER retention and ER-associated degradation as shown previously by us and others ([@B38]; [@B6]). Depletion of CCT7 resulted in lower total and cell-surface expression for both TPβ and β~2~AR. It also caused redistribution of the receptors to aggresomes, drastically in the case of TPβ. This indicates that CCT7 is involved in preventing aggregation and degradation of the receptors. Of note, it was shown that mutation of CCT7 in yeast caused the VHL protein to accumulate in juxtanuclear aggregates ([@B2]), similar to what we observed for the receptors in our study. It is also interesting that the misfolded GPCR rhodopsin P23H mutant, associated with autosomal-dominant retinitis pigmentosa, also accumulates in aggresomes and is ubiquitinated and degraded by the proteasome ([@B49]), further supporting the notion that inappropriately folded GPCRs are targeted to aggresomes. The receptors in CCT7-depleted cells colocalized with a subfraction of the misfolded proteins stained by the PROTEOSTAT aggresome dye, with a juxtanuclear localization that overlapped partially with the Golgi. Aggregated inclusion bodies and misfolded proteins accumulate in aggresomes ([@B57]). This aggregation process is more likely to occur cotranslationally while hundreds of nascent polypeptides chains emerge from the polysomes at the same time in a single localization leading to the improper folding ([@B23]). The aggresomal particles are then transported toward the microtubule organizing center via dynein to be sequestered in a large single structure called the aggresome ([@B22]). This juxtanuclear sequestration is a nontoxic cellular response to misfolded proteins and is known to help the recruitment of various chaperones such as Hsc70, Hsp90, and even the CCT/TRiC complex as an ultimate resort for refolding ([@B22]; [@B59]). This further supports our data showing that the β~2~AR, and particularly TPβ, accumulate in aggresomes in CCT7-depleted cells. Proteins that cannot be refolded will enter both lysosomal and proteasomal degradation pathways ([@B23]).

The β~2~AR was less affected than TPβ by CCT7 expression knockdown. This suggested that the β~2~AR might take advantage of complementary folding pathways. Indeed, as nascent polypeptide chains emerge from ribosomes they are met by Hsc70. The latter may act together with CCT/TRiC in the folding of different polypeptides. Other newly synthesized polypeptides can fold spontaneously or be assisted by Hsc70. Alternatively, they can be passed from Hsc70 to Hsp90 for subsequent folding ([@B61]). Our data showed that Hsp90 coimmunoprecipitated with the β~2~AR, whereas its interaction with TPβ was negligible. This indicates that nascent GPCR polypeptides can be subjected to distinct folding pathways depending on the receptor and could explain, at least in part, why the β~2~AR cell-surface expression was less sensitive to CCT7 depletion than TPβ. Involvement of Hsp90 has been reported in the folding and trafficking of other GPCRs, such as the melanocortin-4 receptor ([@B34]), the prostaglandin D~2~ receptor ([@B10]), the adeno-sine A~2~A receptor ([@B8]), and the α~2c~-adrenergic receptor ([@B20]).

Our results demonstrated that Trp^334^ is crucial for TPβ to bind to CCT7 and that introduction of a tryptophan residue in the TPα C-terminus promoted its interaction with CCT7. Strikingly, the TPβ W334Q and TPα Q333W substitutions conferred properties that corresponded to the other wild-type TP isoform. It has been shown that hydrophobic interactions are involved in the binding of CCT subunits to actin, VHL, and Gβ proteins ([@B26]). In particular, replacement of Trp^117^ substantially reduced the binding of the VHL protein to CCT ([@B19]), similar to what we observed for TPβ. It may be that CCT-complex proteins serve to facilitate early interactions between receptors and Gβ proteins during their biosynthesis and favor their proper assembly ([@B18]). However, the fact that we identified a single residue, Trp^334^, that dictates the interaction between CCT7 and TPα or TPβ and their maturation and trafficking properties strongly supports that CCT7 acts, at least in part, directly on the receptors.

It might be counterintuitive that TPβ Trp^334^ is a major determinant of the TPβ-CCT7 interaction but its mutation does not reduce total TPβ protein expression and promotes maturation and cell-surface expression of the receptor. It has been shown that depletion of a single CCT subunit leads to the codepletion of the other CCT/TRiC complex subunits ([@B21]). Thus expression knockdown of CCT7 could destabilize or deplete the CCT/TRiC complex, leading to receptor aggregation and degradation. Furthermore, it is common for substrates using the chaperonin complex to interact with multiple subunits through distinct determinants ([@B62]). It is reasonable to speculate that GPCRs using the CCT/TRiC complex will interact with multiple domains of many CCT subunits. This could explain, in part, why TPβ W334Q displays decreased CCT7 binding but is still able to mature and fold correctly, perhaps by interacting with other CCT domains or subunits through its ICL3, for example. The fact that TPβ W334Q showed improved maturation and cell-surface expression compared with wild-type TPβ suggests that the CCT7 interaction with Trp^334^ retains TPβ in the CCT/TRiC folding process during or before ER processing. In this regard, it is interesting to note that CCT7 displays holdase activity for substrates, in that it possesses the ability to bind folding intermediates of client proteins and to prevent aggregation without actively participating in the folding process itself ([@B43]). CCT7 was reported to have a low affinity for ATP and to be unable to bind it at physiological concentrations. High- and low-affinity CCT subunits were shown to be spatially segregated within two contiguous hemispheres in the CCT/TRiC ring, generating an asymmetric power stroke proposed to drive the folding cycle. This uncommon mode of ATP usage is thought to serve in coordinating a directional mechanism underlying the unique ability of CCT/TRiC to fold complex proteins ([@B45]). Further experiments will be needed to fully understand the specificity and the role of the various CCT subunits and their binding determinants involved in GPCR folding.

In summary, we have characterized a direct and functional interaction between a subunit of the CCT/TRiC chaperonin complex and GPCRs. We have provided evidence that distinct nascent GPCRs can undergo alternative folding pathways and that CCT/TRiC is critical in preventing aggregation of some GPCRs and in promoting their proper maturation and expression.

MATERIALS AND METHODS
=====================

Reagents
--------

Monoclonal anti-HA (3F10) antibody was from Roche Applied Science (Pleasanton, CA). Anti-GAPDH polyclonal antibody, anti--TCP-1~η~ (CCT7) (E-20) goat polyclonal antibody, anti-β~2~AR (H-73) polyclonal antibody, and protein G--agarose beads were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Texas Red anti-goat immunoglobulin G (IgG) was from Jackson ImmunoResearch (West Grove, PA). Alexa Fluor 488, Alexa Fluor 633 anti-rabbit IgG, and ProLong Gold antifade reagent were purchased from Invitrogen (Carlsbad, CA). Anti--c-Myc (9E10) monoclonal antibody was from Covance (Montreal, Canada). Anti--Myc-horseradish (HRP) polyclonal antibody was from Abcam (Toronto, Canada). Anti--rabbit-HRP IgG and anti--mouse-HRP IgG were purchased from GE Healthcare (Baie d\'Urfé, Canada). Anti--goat-HRP IgG was from R&D Systems (Minneapolis, MN). Polyclonal anti-FLAG, the alkaline phosphatase--conjugated anti-mouse antibodies, and the alkaline phosphatase substrate kit were purchased from Sigma-Aldrich (Oakville, Canada). PROTEOSTAT Aggresome Detection Kit was from Enzo Life Sciences (Farmingdale, NY). Goat anti--GST-HRP antibody was purchased from Bethyl Laboratories (Montgomery, TX). Purified mouse anti-GM130 was purchased from BD Transduction Laboratories (San Jose, CA).

Plasmid constructs
------------------

CCT7 cDNA (NCBI accession NM_006429.3) was amplified from a human leukocyte cDNA library. MYC-tagged CCT7 construct was generated by PCR using the Phusion High-Fidelity PCR system (New England Biolabs, Whitby, Canada) and primers containing the MYC epitope in-frame with the N-terminus of the CCT7 open reading frame. The CCT7-MYC PCR fragment was digested with *Bam*HI and *Eco*RI and ligated into pcDNA3 and pRSET A vectors digested with the same restriction enzymes. Receptor constructs do not contain a signal peptide. HA-TPβ and HA-TPα site-directed mutagenesis was carried out by PCR using pcDNA3-HA-TPβ and pcDNA3-HA-TPα constructs ([@B39]) as templates. TPβ pGEX-4T1 constructs were made as previously described ([@B11]). β~2~AR and the yeast two-hybrid pAS2-1-TPβCT constructs were described previously ([@B37]; [@B11]). The integrity of the coding sequences of all constructs was confirmed by dideoxy DNA sequencing. HA-MOR and FLAG-DOR constructs were a kind gift of Louis Gendron (Université de Sherbrooke).

Yeast two-hybrid screen
-----------------------

A yeast two-hybrid screen was performed following the two-hybrid system standard protocol (Gietz and Woods, 2002). Briefly, a plasmid containing the C-terminus of TPβ (pAS2-1-TPβCT) was transformed into the yeast strain pJ69-4α using the lithium yeast transformation protocol (Gietz and Woods, 2002). This stably transformed clone was then transformed with a human HeLa cell MATCHMAKER cDNA Library or with the empty pGAD-424 plasmid (Clontech, Mountain View, CA). Positive clones were initially selected for growth in the absence of histidine, and interactions were confirmed by growth on quadruple-selective medium (Trp^−^, Leu^−^, His^−^, and Ade^−^). pGADGH plasmids containing the library inserts from positive colonies were isolated and transformed into the DH10B bacterial strain. Plasmids were extracted from DH10B cells and transformed once more into yeast with either the bait (pAS2-1/TPβCT) or the negative control (pAS2-1) and plated on quadruple-selective medium (Trp^−^, Leu^−^, His^−^, and Ade^−^) to confirm the interaction. The selected plasmids were then sequenced by dideoxy DNA sequencing, and the identities of the clones were determined by using the NCBI BLAST alignment tool.

Cell culture and transfection
-----------------------------

Human embryonic kidney 293 (HEK 293) cells were maintained in DMEM (Invitrogen) supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere containing 5% CO~2~. Transient transfection of HEK 293 cells grown to 50--70% confluence was performed using the *Trans*IT-LT1 Reagent (Mirus, Madison, WI) according to the manufacturer's instructions. Empty pcDNA3 vector was added to keep the total DNA amount constant per plate. Stably TPβ- and β~2~AR-expressing HEK 293 cells were generated as previously described ([@B4]; [@B38]) and cultured the same way as transiently transfected cells except for the addition of 200 μg/ml of G418.

The synthetic duplex oligonucleotide named HSC.RNAI.N006429.12.4 targeting the human CCT7 gene and the negative control DsiRNA (DS NC1, catalogue number- 51-01-14-03) were purchased from Integrated DNA Technologies (Coralville, IA). HEK 293 cells were transfected with 50 nM oligonucleotides using the Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's recommendations, except for the following modifications: Cells were seeded directly into the transfection mix at twice the cell density indicated in the basic protocol. Reverse transcriptase-PCRs were carried out to confirm that the CCT7 DsiRNAs did not reduce the mRNA levels of the receptors.

Immunoprecipitations
--------------------

HEK 293 cells were transiently transfected with the indicated constructs and maintained as described above for 48 h. Cells were then washed with ice-cold phosphate-buffered saline (PBS) and harvested in 300 μl of lysis buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 0.5% deoxycholate, 0.1% SDS, 10 mM Na~4~P~2~O~7~, 1% IGEPAL, and 5 mM ethylenediaminetetraacetic acid) supplemented with protease inhibitors (10 μM pepstatin, 10 μM antipain, 10 μM leupeptin, and 10 μM chymostatin \[Sigma-Aldrich\]). After 60 min of incubation in lysis buffer at 4°C with rotation, the lysates were then centrifuged for 20 min at 14,000 × *g* at 4°C. One microgram of specific antibodies was added to the supernatant. After 3 h of incubation at 4°C with rotation, 40 μl of 50% protein G--agarose beads was added, followed by overnight incubation at 4°C. Samples were then centrifuged for 1 min in a microcentrifuge and washed four times with 1 ml of lysis buffer. Immunoprecipitated proteins were eluted by addition of 35 μl of SDS sample buffer, followed by a 60 min incubation at room temperature. Initial lysates and immunoprecipitated proteins were analyzed by SDS--PAGE and immunoblotting with specific antibodies. Endogenous immunoprecipitations were performed in native HEK 293 cells. Cells were harvested and processed as described above, except proteins were immunoprecipitated overnight using 2 μg TCP-1~n~ (CCT7)-specific or appropriate control antibodies and 40 μl of 50% protein G--agarose beads.

Immunofluorescence staining and confocal microscopy
---------------------------------------------------

For colocalization experiments, HEK 293 cells stably expressing HA-β~2~AR or HA-TPβ were plated in six-well plates at a density of 5 × 10^4^ cells/well directly onto coverslips coated with 0.1 mg/ml poly-[l]{.smallcaps}-lysine (Sigma-Aldrich) and transfected with control or CCT7-specific DsiRNAs. The cells were fixed after a 72 h incubation with 2% (vol/vol) paraformaldehyde in PBS for 30 min at 4°C. Subsequently cells were washed twice with PBS and permeabilized for 10 min with 0.1% Triton X-100 in PBS and blocked for 30 min with 0.1% Triton X-100 in PBS containing 0.5% (wt/vol) bovine serum albumin (BSA) at room temperature. After two washing steps with 0.1% Triton X-100 in PBS, cells were incubated 2 h with HA-specific and CCT7-specific (not for IgG Ctrl conditions) antibodies diluted in blocking buffer at room temperature. The cells were washed twice with permeabilization buffer, blocked again for 10 min, and incubated with appropriate secondary antibodies for 60 min at room temperature or with the Proteostat aggresome dye according to the manufacturer's recommendations. Cells were then washed three times with PBS, and coverslips were mounted using ProLong Gold antifade reagent. Confocal microscopy was performed using a scanning confocal microscope (FV1000; Olympus, Richmond Hill, Canada) coupled to an inverted microscope with a 60× oil-immersion objective (Olympus), and all laser parameters were conserved between all image acquisitions for the same figure. Images were processed using Fluoviewer 2.0 software (Olympus), and Mander's colocalization coefficients ([@B16]) were calculated using the same threshold for fluorescent background elimination across all images, since they were acquired with the same parameters.

Measurement of cell-surface receptor expression by ELISA
--------------------------------------------------------

Quantification of cell-surface receptor expression was carried out as we described before ([@B10]). Briefly, 5 × 10^4^ HEK 293 cells stably expressing HA-β~2~AR or HA-TPβ were plated in 24-well plates precoated with 0.1 mg/ml poly-[l]{.smallcaps}-lysine (Sigma-Aldrich). Cells were transfected with the indicated DsiRNAs and then maintained for an additional 72 h. The cells were fixed in 3.7% (vol/vol) formaldehyde/Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.5, and 150 mM NaCl) for 5 min at room temperature. Cells were then washed twice with TBS, and nonspecific binding was blocked by incubation with TBS containing 1% BSA for 30 min. A monoclonal HA-specific antibody was then added at a dilution of 1:2000 in TBS--BSA (1%) for 60 min. Following incubation with the primary antibody, cells were washed twice and blocked again with TBS--BSA (1%) for 10 min. Cells were then incubated with an alkaline phosphatase--conjugated goat anti-mouse antibody at 1:10,000 dilution in TBS--BSA (1%) for 60 min. Cells were washed twice with TBS, and 250 μl of a colorimetric alkaline phosphatase substrate was added as per the manufacturer's instructions. The plates were then incubated at 37°C until a yellow color appeared. The reaction was stopped by the addition of 250 μl of NaOH (0.4 M). A 200 μl aliquot of the colorimetric reaction was taken, and the absorbance was measured at 405 nm using a Titertek Multiskan MCC/340 spectrophotometer. All conditions were done in triplicate for each experiment.

Recombinant protein production and histidine pull-down analysis
---------------------------------------------------------------

For production of His-tagged proteins, a PCR fragment corresponding to the cDNA coding for full-length CCT7 was inserted into the pRSETA expression vector (Invitrogen) as described above. This construct was used to produce the fusion protein in OverExpressTM C41 (DE3) *Escherichia coli* strain (Avidis, Roubais, France) by following the manufacturer's instructions. The recombinant proteins were purified using nickel--nitrilotriacetic acid--agarose resin (Qiagen, Toronto, Canada) as indicated by the manufacturer. The cDNA fragments coding for the C-terminus and intracellular loops of β~2~AR or TPβ introduced in the pGEXT-4T1 vector (Amersham Biosciences, Baie d\'Urfé, Canada) were used to produce GST fusion proteins in the OverExpressTM C41 (DE3) *E. coli* strain, which were purified using glutathione--Sepharose 4B beads (Amersham Biosciences) and eluted according to the manufacturer's indications. Purified recombinant proteins were analyzed by SDS--PAGE followed by Coomassie brilliant blue R-250 staining. Five micrograms of each GST-tagged fusion protein was incubated with 5 μg of the purified nickel--nitrilotriacetic acid--agarose His-tagged CCT7 in wash buffer (300 mM NaCl, 50 mM NaH~2~PO~4~, 20 mM imidazole, 0.5% Triton X-100, and 2 mM dithiothreitol) supplemented with protease inhibitors (9 nM pepstatin, 9 nM antipain, 10 nM leupeptin, and 10 nM chymostatin). Binding reactions were then washed three times with wash buffer. SDS sample buffer was added to the binding reactions, and the tubes were boiled for 5 min. The pull-down reactions were analyzed by Western blotting with the indicated specific antibodies.

Deglycosylation assays
----------------------

Receptors were transiently expressed in HEK 293 cells in 60 mm plates, and cell lysates were prepared as described above. Protein concentration of samples was determined with the *DC* (detergent-compatible) Bio-Rad (St-Laurent, Canada) protein assay. For Endo Hf experiments, volumes of lysates corresponding to 40 μg protein were denatured in glycoprotein denaturing buffer 1× (New England Biolabs) for 30 min at 37°C followed by the addition of glycobuffer 1× (New England Biolabs) and 10,000 U/ml of Endo Hf (New England Biolabs). Samples were incubated with the enzyme for 5 h at 37°C and analyzed by Western blot.

Statistical analysis
--------------------

Statistical analysis was performed using Prism version 5.0 (GraphPad Software) using a two-tailed Student's *t* test or one-way analysis of variance with multiple comparisons. Data were considered significant when *p* values were \< 0.05 (\*), \< 0.01(\*\*), \< 0.001 (\*\*\*), or \< 0.0001 (\*\*\*\*). Nonsignificant values are abbreviated as "ns."
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